TECENTRIQ may be used with the medicine paclitaxel protein-bound when your breast cancer: has spread or cannot be removed by surgery, and. Triple-negative breast cancer is breast cancer that is: estrogen-receptor-negative progesterone-receptor-negative HER2-negative. Tecentriq (atezolizumab Side Effects, How it Works, and More Apr 1 20Metastatic breast cancer is cancer that has spread to other parts of the body away from the breast, such as the bones or liver. Org Jul 2 20Tecentriq is an immunotherapy that can be used in combination with Abraxane as a first treatment for certain advanced-stage or metastatic triple-negative, PD-L1-positive breast cancers.
Tecentriq is approved to treat a specific type of triple-negative breast cancer. Tecentriq is an immune checkpoint inhibitor medicine that stops PD-from binding to PD-L which allows T cells to attack the cancer cells). TECENTRIQ, in combination with paclitaxel protein-boun is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC ) whose tumors express PD-L(PD-L1stained tumor-infiltrating immune cells IC of any intensity covering of the tumor area).